Send to

Choose Destination
J Korean Neurosurg Soc. 2017 Mar;60(2):195-204. doi: 10.3340/jkns.2016.0505.011. Epub 2017 Mar 1.

A Nation-Wide Epidemiological Study of Newly Diagnosed Primary Spine Tumor in the Adult Korean Population, 2009-2011.

Sohn S1,2,3,4, Kim J5, Chung CK1,2,3,6, Lee NR7, Sohn MJ8, Kim SH9.

Author information

Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Neuroscience Research Institute, Seoul National University Medical Research Center, Seoul, Korea.
Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.
Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Nursing, College of Medicine, Chosun University, Gwangju, Korea.
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Korea.
National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
Department of Neurosurgery, Ilsan Paik Hospital, College of Medicine, Inje University, Goyang, Korea.
Department of Radiation Oncology, St. Vincent's Hospital, School of Medicine, The Catholic University of Korea, Suwon, Korea.



This 2009-2011 nation-wide study of adult Koreans was aimed to provide characteristics, medical utilization states, and survival rates for newly diagnosed patients with primary nonmalignant and malignant spine tumors.


Data for patients with primary spine tumors were selected from the Korean Health Insurance Review and Assessment Service database. The data included their age, sex, health insurance type, co-morbidities, medical cost, and hospital stay duration. Hospital stay duration and medical costs per person occurring in one calendar year were used. In addition, survival rates of patients with primary malignant spine tumors were evaluated.


The incidence rate of a primary spine tumor increased with age, and the year of diagnosis (p≤0.0001). Average annual medical costs ranged from 1627 USD (pelvis & sacrum & coccyx tumors) to 6601 USD (spinal cord tumor) for primary nonmalignant spine tumor and from 12137 USD (spinal meningomas) to 20825 USD (pelvis & sacrum & coccyx tumors) for a primary malignant spine tumor. Overall survival rates for those with a primary malignant spine tumor were 87.0%, 75.3%, and 70.6% at 3, 12, and 24 months, respectively. The Cox regression model results showed that male sex, medicare insurance were significantly positive factors affecting survival after a diagnosis of primary malignant spine tumor.


Our study provides a detailed view of the characteristics, medical utilization states, and survival rates of patients newly diagnosed with primary spine tumors in Korea.


Epidemiology; Neoplasms; Population; Spine

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center